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Abstract 
Background: Berardinelli-Seip congenital lipodystrophy (BSCL) was initially described by Berardinelli in Brazil in 1954 
and 5 years later by Seip in Norway. It is an autosomal recessive disease that leads to a generalized deficit of body fat, 
evolving with diabetes and hypertriglyceridemia. The aim of this study was to describe the clinical and laboratory 
characteristics of a large series of patients with BSCL.
Methods: This is a cross-sectional study of patients with BSCL. A total of 54 cases of BSCL were diagnosed, treated 
and followed for the past 17 years. We report clinical and laboratorial data of 44 of those patients.
Results: There was a predominance of female patients (27 patients), and the mean age was 21.3 ± 13.7 years old. The 
majority of patients (30/44; 68.2 %) were diabetic, and almost half of them (14/30 patients, 46.7 %) were on insulin. The 
mean body mass index was 19.6 ± 3.3 and the mean body fat measured by dual-energy X-ray absorptiometry (DEXA) 
was 5.4 ± 0.8 %. Acanthosis nigricans, acromegaloid facies, atrophic cheeks, prognathism, phlebomegaly, and muscle 
hypertrophy were the most common clinical features. Only two patients had triglyceridemia lower than 150 mg/dl 
without the use of lipid-lowering drugs. Hyperinsulinemia was present in the majority of patients, and leptin values 
were very low in all patients.
Conclusions: We report one of the largest series of patients with BSCL treated at a single medical center. Earlier 
identification of the mutations and a better understanding of the pathophysiology can aid to better treatment and 
decrease complications, potentially improving life quality and expectancy.
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Background
Diabetes, especially Type 2, has become a world health 
problem, usually resulting from excessive weight and 
increased visceral fat. However, other less common 
forms of diabetes occur, some because of specific genetic 
alterations. Congenital generalized lipodystrophy (CGL) 
was first described in Brazil in 1954 by Waldemar Berar-
dinelli in two children [1], and 5 years later Martin Seip 
in Norway also described three other similar cases [2]. 
Berardinelli-Seip congenital lipodystrophy (BSCL) is 
clinically characterized by hepatosplenomegaly, fatty 
liver, altered carbohydrate metabolism, severe insulin 
resistance, hyperinsulinemia, acromegaloid habitus, and 
dyslipidemia.
BSCL clinical characteristics and outcome are relatively 
well known, and new mutations recently described have 
allowed a better understanding of the disease’s patho-
physiology. Currently, the disease is classified into four 
types according to clinical characteristics and the type 
of mutations. Genes involved in the pathophysiology of 
BSCL are responsible for adipogenesis and lipogenesis, 
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droplets [4], development and maturation of adipocytes 
[5].
The BSCL is an autosomal recessive syndrome with 
around 500 cases reported in the world [6, 7]. In Bra-
zil, in the State of Rio Grande do Norte, we have diag-
nosed, treated, and followed 54 cases of BSCL in the past 
17 years. The aim of this study was to describe the clinical 
and laboratory characteristics of a large series of patients 
with BSCL, correlating the findings with the pathophysi-
ology of the disease.
Methods
Patients
We report clinical, laboratory, and genetic features of 
44 patients with CGL who are followed at the endocrine 
clinic of Hospital Universitário Onofre Lopes, Natal-RN, 
Brazil. As the disease has an autosomal recessive inher-
itance, our large number of patients is due to consan-
guinity, common in the region. Furthermore, with the 
increase in the number of diagnosed patients, it was eas-
ier to detect similar cases in the population.
Variables studied
Data were obtained from history and physical examina-
tion during a regular visit to the outpatient endocrine 
clinic at Hospital Universitário Onofre Lopes or col-
lected retrospectively from hospital records. Arterial 
hypertension was considered if the patient was on anti-
hypertensive drug treatment or if repeated blood pres-
sure measurements were higher than 140 ×  90  mmHg. 
Hypertriglyceridemia was diagnosed if serum triglycer-
ides were higher than 150  mg/dl and/or patient was on 
lipid-lowering drugs (fibrates). Criteria of American Dia-
betes Association (ADA) were considered for the diagno-
sis of diabetes [8].
Laboratory and image investigations
Glycemia, glycated hemoglobin (HbA1c), total choles-
terol, HDL cholesterol, LDL cholesterol (calculated by 
Friedewald formula if triglyceride level was lower than 
400  mg/dl), non-HDL cholesterol (calculated by total 
cholesterol minus HDL cholesterol), triglyceridemia, 
urea, creatinine, insulin, and leptin were measured in 
serum after an overnight fasting. HOMAIR (homeo-
stasis model assessment) was calculated (fasting gly-
cemia (mmol/L)  ×  fasting insulin (μU/ml))÷22.5) [9] 
and a value higher than 2.7 was considered as indica-
tive of insulin resistance [10]. To evaluate liver damage 
by steatosis, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) and, gamma-glutamyl trans-
peptidase (GGT) were measured. Genetic analysis was 
performed as described elsewhere [11]. Body fat percent-
age measured by DEXA scan (Lunar ® DPX) was available 
from 20 patients. Liver biopsy and ultrasound were not 
performed.
Statistical methods
Parametric data are expressed as mean ± standard devia-
tion and non-parametric data are expressed as median 
(minimum–maximum). Proportions are presented as n 
(%). T test was used to compare mean of parametric data, 
and Mann–Whitney test was used for non-parametric 
data. The Shapiro–Wilk test was used to analyze normal-
ity data distribution. To evaluate the correlation between 
two variables, Pearson (parametric variables) and Spear-
man (nonparametric variables) correlation coefficients 
were used. A p value <0.05 was considered statistically 
significant. We used SPSS, version 22, to analyze the data.
Results
Subjects and family history
Clinical characteristics of patients are shown in Table 1. 
There was a predominance of female patients (27 
patients, 61.4 %) and the mean age was 21.3 ± 13.7 years 
old. Consanguinity between parents was reported by 
72.4  % of patients with available data. There were no 
differences in anthropometric and laboratory findings 
of patients with and without parents’ consanguinity 
(p  >  0.05). Twenty-seven patients (61.4  %) had, at least, 
one relative affected by the syndrome. Regarding the lipid 
and glucose control, having a positive family history of 
the syndrome did not confer a worse outcome of the dis-
ease. The vast majority of patients (30/44; 68.2  %) were 
diabetic, and almost half of them (14 patients, 46.7  %) 
were on insulin. The mean age of diabetes onset was 
15.8 ± 7.1 years old. Diabetics were older than non-dia-
betics (27.3 ± 11.0 vs. 8.5 ± 9.6 year-old, p < 0.001). The 
mean duration of diabetes was 11.8  ±  7.3  years. Arte-
rial hypertension, defined as the use of antihypertensive 
drugs, was present in 12 patients (27.2 %).
Phenotype
Anthropometric characteristics are described in Table 1. 
Only two patients were overweight (BMI 25.1 and 
27.2 kg/m2). BMI correlated positively with age (r = 0.72, 
p < 0.001), waist (r = 0.86, p < 0.001), % body fat (r = 0.53, 
p = 0.03), systolic blood pressure (r = 0.39, p = 0.02), and 
HbA1c (r = 0.58, p = 0.001). Twenty patients had avail-
able data of body fat measured by DEXA analysis and, as 
expected, all of them had very low body fat (5.4 ± 0.8 %). 
On physical examination (Fig.  1), acanthosis nigricans, 
acromegaloid facies, atrophic cheeks (loss of Bichat’s fat 
ball), prognathism, phlebomegaly (Fig.  2b), and muscle 
hypertrophy were the most common findings. Acantho-
sis nigricans, a cutaneous marker of insulin resistance, 
was very frequent, but acrochordons, another important 
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cutaneous alteration in insulin resistance, were present 
only in a minority of patients. No patient had umbili-
cal hernia. One patient had a myocardial infarction at 
18 years old, and another patient had bilateral occlusion 




Biochemical tests are presented in Table 2. As the major-
ity of patients were diabetic, glycemia and glycated 
hemoglobin were elevated. As expected, diabetics had 
higher glycemia (152.0 [67.0–424.0] vs. 71.0 [66.0–86.0] 
mg/dl, p  <  0.001) and glycated hemoglobin (8.3  ±  1.9 
vs. 5.4 ± 0.7 %, p < 0.001) than non-diabetics. Glycemic 
control was poor. Only 9 out of 30 (30.0 %) patients with 
diabetes had HbA1c lower than 7 %, and the majority (16 
out of 30 patients, 53.3  %) had values greater than 8  %. 
Hypertriglyceridemia and, consequently, low HDL were 
common findings. No patients had HDL above 45 mg/dl 
and 22 patients had HDL < 30 mg/dl. Only two patients 
(both were children) had normal triglyceridemia. Diabet-
ics had higher triglyceridemia than non-diabetics (330.0 
[119.0–1121.0] vs. 190.5 [124.0–422.0] mg/dl, p = 0.009). 
Approximately two-thirds of the patients had normal 
values of aminotransferase (AST  <  40  mg/dl—28/44 
patients, 63.6 %; ALT < 40 mg/dl—27/44 patients, 61.4 %) 
and GGT (29/44 patients; 65.9  %). Women had higher 
values of GGT than men (GGT 35.0 [11.0–552.0] vs. 24.0 
[14.0–114.0] mg/dl, p  =  0.019). There were no gender 
differences regarding AST and ALT.
Hormones (Table 2)
Forty-two patients had insulin measured. Hyperinsu-
linemia was present in the majority of patients (33/42 
Table 1 Clinical characteristics of patients
SD standard deviation
a  Percentage of available data
b  Twelve patients (27.2 %) were on antihypertensive drugs
Mean ± SD n (%)
Age (years) 21.3 ± 13.7
Gender –
 Female – 27 (61.4)
 Male – 17 (38.6)
Diabetes – 30 (68.2)
Arterial hypertension – 12 (27.3)
Hypertriglyceridemia – 42 (95.5)
Body mass index (Kg/m2) 19.6 ± 3.3 –
Body fat (%) 5.4 ± 0.8 –
Waist (cm) 76.4 ± 8.8 –
Waist/hip ratio 0.93 ± 0.07 –
Heart rate (bpm) 85.3 ± 10.7 –
Systolic blood pressure (mmHg)b 122.0 ± 16.2 –
Diastolic blood pressure (mmHg)b 75.4 ± 9.7 –
Acanthosis nigricans – 23 (79.3)a
Acromegaloid facies – 42 (95.5)
Atrophic cheeks – 43 (97.7)
Prognathism – 40 (90.9)
Muscle hypertrophy – 35 (79.5)
Phlebomegaly – 36 (100)a
Fig. 1 Clinical features of BSCL—Two patients with BSCL type 2. 
Acromegaloid facies, prognathism, atrophic cheeks, abdominal 
distension (female)
Fig. 2 a Abdominal distension (hepatomegaly), umbilical protrusion, 
and phlebomegaly b in two patients with Berardinelli-Seip syndrome
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patients; 78.6  %). Patients were classified according 
to age (less than 10 and more than 10  years), and we 
observed that older patients had more hyperinsulinemia 
than younger patients (90.6  % [29/32] vs. 40  % [4/10], 
p  =  0.003). The HOMAIR was consistent with insulin 
resistance (HOMAIR  >  2.7) in 33 patients (78.6  %), and 
correlated positively with total cholesterol (r  =  0.48, 
p =  0.007), triglycerides (r =  0.42, p =  0.02), and GGT 
(r = 0.45, p = 0.012). Leptin values were very low in all 
patients (n = 39—Table 2); the higher value was 2.3 ng/
ml (normal values for women <14.7 ng/ml and for men 
<7.4  ng/ml) and almost half of the patients had values 
lower than 1.0  ng/ml. There was no difference between 
children’s and adults’ leptin values (0.9 [0.5–1.1] vs. 1.0 
[0.4–2.3] ng/ml, p > 0.05).
Genetics
Twenty-nine patients (65.9  %) had a genetic diagnosis. 
Mutation of the gene BSCL2 (seipin—Gng3lg669insA) 
was present in 93.1 % of the cases (27 patients). The other 
two patients were sisters and showed a mutation in the 
gene AGPAT2 (AGPAT2 A712T). Of the 15 patients who 
had no genetic analysis, one was the brother of the two 
patients with the mutation in AGPAT2 and probably also 
had this mutation.
Discussion
We report a series of patients with BSCL. This is a rare 
syndrome and case series reported in the literature are 
usually gathered from patients of several hospitals/clinics 
[12, 13]. Our patients are accompanied in a single setting, 
the endocrinology clinic of the University Hospital Ono-
fre Lopes, in Natal/RN, Brazil. Over the past 17  years, 
approximately 54 patients were diagnosed and monitored 
in this hospital. As consanguineous relationships exist in 
certain regions of our state, every year we still do some 
new diagnosis of this syndrome. In some cases, this diag-
nosis is as early as the first year of life, but in others, it 
may be much later, with the patient already presenting 
chronic complications of diabetes. We present here an 
overview of the clinical and laboratory findings of one of 
the largest series of patients followed in a single medical 
center, by the same medical team.
Since the phenotype of BSCL is typical (acromega-
loid facies, muscle hypertrophy, acanthosis nigricans, 
decreased body fat, mild enophthalmos, among oth-
ers), the clinical diagnosis of BSCL is relatively easy but 
requires a clinical suspicion (Fig. 1). Quite often, parents 
report that since birth or early in life the child had a dif-
ferent appearance, however, diagnosis is usually delayed. 
After our first cases, the identification of other cases was 
easier, since the medical staff became more aware of the 
potential cases. In addition, families have become pro-
active, further facilitating early diagnosis.
Consanguineous marriages are not rare, occurring 
in about 10 % of the world population [14]. This signifi-
cantly increases the risk of developing genetic diseases, 
like BSCL. In fact, this is one of the most important risk 
factors in our study. More than two-thirds of our patients 
(72.4  %) reported consanguinity between parents and 
more than half (61.4 %) had, at least, one relative affected 
by the syndrome. The consanguinity rate can be even 
bigger; one patient only discovered the family relation-
ship of her parents when she searched it until the fourth 
generation.
The majority of our patients were BSCL Type 2. This 
could help to explain the low average age of the patients 
(21 years) since this type is more severe and has a greater 
predisposition to premature death. AGPAT2 gene is 
essential in lipogenesis, while BSCL2 is also involved in 
the differentiation of pre-adipocytes and adipocyte matu-
ration. In this setting, BSCL Type 2 has the most severely 
Table 2 Laboratory findings of patients with BSCL
All comparisons between non-diabetics and diabetics have p < 0.05
AST aspartate aminotransferase; ALT alanine aminotransferase; GGT gamma-
glutamyl transpeptidase; HOMA homeostasis model assessment
Test Result Reference range
Glycemia (mg/dl) 89 (55–424) 70–99
 Non diabetic 71 (55–86)
 Diabetic 152 (67–424)
Glycated hemoglobin (%) 7.4 ± 2.1 <5.7
 Non diabetic 5.4 ± 0.7
 Diabetic 8.3 ± 1.9
Total cholesterol (mg/dl) 170 (106–316) <200
HDL cholesterol (mg/dl) 30.3 (18–44) >40 (>50)
LDL cholesterol (mg/dl) 98.6 ± 40.6 –
Non HDL cholesterol (mg/dl) 147.9 ± 43 –
Triglyceridemia (mg/dl) 276 (119–1121) <150
 Non diabetic 190.5 (124–422)
 Diabetic 330 (119–1121)
Urea (mg/dl) 26 (10–74) 15–45
Creatinine (mg/dl) 0.5 (0.3–1.4) 0.6–1.2
AST (mg/dl) 31 (13–98) <40
ALT (mg/dl) 35 (10–210) <40
GGT (mg/dl) 31.5 (11–552)
 Women 35 (11–552) <38
 Men 24 (14–114) <55
Insulin (mUI/ml) 25.8 (2.0–164.0) <16
 Patients <10 years 11.0 (2.0–41.0)
 Patients >10 years 27.8 (4.9–164.0)
HOMAIR 7.3 (0.3–73.8) <2.7
Leptin (ng/ml) 1.0 (0.4–2.3)
 Women 1.0 (0.4–2.3) <14.7
 Men 0.9 (0.5–1.7) <7.4
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affected phenotype, with an almost complete lack of body 
fat [15, 16]. We can divide the adipose tissue into meta-
bolic (subcutaneous, intermuscular, intra-abdominal, 
intrathoracic, bone marrow, etc.) and mechanical (palms, 
soles, orbits, periarticular). Both (metabolic and mechan-
ical) are decreased in Type 2, while mechanical fat is 
commonly preserved in Type 1 [6, 15].
Recently, seipin has been described with functions 
beyond those in adipose tissue. It seems to be an impor-
tant protein in spermatogenesis as well as in the nerv-
ous system [17]. Seipin knockout rats have reduced 
brain weight and infertility with azoospermia [17]. 
Some studies have linked seipin defects with motor 
neuron disease [18]. Seipin is expressed in the cerebellar 
cortex, cerebellum, and hypothalamus, and have a sig-
nificant action on neurotransmission, regulating excita-
tory synaptic transmission [16, 19]. There is a tendency 
for a reduction in brain volume in patients with BSCL2 
mutations, but that does not seem to be due to brain 
atrophy [17]. In the literature, when evaluated using 
specific questionnaires, intellectual impairment was 
more frequent in Type 2 than in Type 1 (78 vs. 10  %) 
[20]. We did not assess cognitive function, but it is easy 
to see during the anamnesis that most BSCL type 2 have 
this difficulty.
We only had patients with Type 1 or Type 2 BSCL. 
Due to the small number of Type 1 patients (AGPAT2 
gene mutation), the comparison between these types was 
not possible. Some clinical features can help to differen-
tiate these types. The extreme lack of body fat together 
with an intellectual deficit favors the clinical diagnosis of 
Type 2 BSCL. Acanthosis nigricans, acromegaloid facies, 
prognathism, atrophic cheeks (loss of Bichat’s fat ball), 
abdominal distension with protruding navel, phlebomeg-
aly, and muscle hypertrophy are other common clinical 
findings (Fig. 1). Acrochordon, a marker of insulin resist-
ance, is not usual in our patients, perhaps because it is 
more frequent in patients with higher BMI [21] and also 
because adipocytes (lacking in BSCL) are usually seen in 
the histopathological examination of this lesion. Eruptive 
xanthomas are not frequent.
In the literature, there are several reports of umbili-
cal hernia in patients with BSCL [12, 22]. None of our 
patients required surgery for umbilical hernia repair, and 
on physical examination, we did not detect any cases of 
hernia. In contrast, the absence of subcutaneous adi-
pose tissue made the enlargement of the umbilicus very 
frequent, being present in almost all patients (Fig.  2a). 
Hepatomegaly may also contribute to the umbilical 
prominence. This umbilical protrusion can be confused 
with a hernia and perhaps this may have happened in 
some cases described in the literature, as we already pub-
lished [23].
Usually, in individuals without BSCL, lipids are stored 
during the feeding state, and this stock is mobilized dur-
ing fasting. Together with other mechanisms (hypo-
leptinemia, insulin resistance, etc.), low body fat would 
explain the increased appetite commonly seen in these 
patients. Quite often, parents complain about the diffi-
culty of controlling the appetite of their children.
Diagnosis confirmation can be done by searching for 
one of the known mutations. Of the 44 patients stud-
ied in our cohort, 29 were genotyped. Clinical features 
together with laboratory and imaging (DEXA) tests can 
help to increase the degree of clinical suspicion. Deter-
mination of body fat by DEXA scan is simple and inex-
pensive. Invariably and consistent with the diagnosis, all 
of our patients submitted to this test had very low body 
fat, rarely exceeding 7 %, even in those with higher BMI. 
Serum leptin measurement is available in many cent-
ers with an acceptable cost. Concordant with the very 
low body fat, serum leptin is usually very low. The com-
bination of clinical features, low body fat measured by 
DEXA and very low serum leptin can make the diagno-
sis. Nevertheless, we still advise looking for the mutation, 
because of the clinical peculiarities of each type.
The majority of our patients were diabetics (67.4  %). 
This is expected because diabetes usually starts early in 
this syndrome (mean age 15  years), and the mean age 
of the group was 21 years. Diabetes was not detected in 
any affected children under the age of 10 years, and their 
serum insulin was lower than that of adults. Interestingly, 
even with higher values of serum insulin, adults develop 
diabetes. This may indicate that, unlike Type 2 diabetes 
where the failure to increase insulin secretion by the beta 
cells is an important factor to the onset of the disease 
[24, 25], in patients with BSCL, the increasing insulin 
resistance appears to be the key determinant. We could 
hypothesize that with age and difficult to deposit fat in 
the adipocyte, the lipids are stored in the liver and mus-
cles, reducing insulin sensitivity and requiring higher 
secretion of the beta cells [22]. These cells continue 
to secrete too much insulin, but it does not seem to be 
enough, and the patient develops diabetes. Serum leptin 
did not differ between adults and children, being very 
low in both groups. This confirms that, as an autosomal 
recessive hereditary disease, BSCL has already started 
since birth, in contrast to insulin resistance that worsens 
with age.
The glycemic control of these patients was not good, but 
this is not a peculiarity of this syndrome. Worldwide and 
specifically in Brazil, only a small percentage of diabetic 
patients has good glycemic control. The analysis of a series 
of more than 5000 type 2 diabetic patients in Brazil showed 
that the mean HbA1c was 8.6 % and only 26 % had HbA1c 
<7 % [26]. The data of our patients were very similar (mean 
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HbA1c 8.3 % and only 30 % with HbA1c <7 %). In recent 
years, we have been diagnosing the BSCL earlier (some 
cases even before 1 year of age). We hope this will allow 
imposing actions that will delay the onset of diabetes, pre-
vent its complications, and improve life expectation.
Hypertriglyceridemia was present in the great major-
ity of patients (42 patients, 95.5 %), being higher in dia-
betics (330.0 [119.0–1121.0] vs. 190.5 [124.0–422.0] mg/
dl, p < 0.05). This is the result of serum accumulation of 
chylomicron and VLDL as well as excessive hepatic pro-
duction due to liver steatosis [27]. The tissue uptake of 
triglycerides is defective due to the inability of adipo-
cytes to store energy. Moreover, the lipolysis caused by 
endothelial lipase and stimulated by insulin is attenuated 
due to insulin resistance [27]. Although hypertriglyceri-
demia is common and acute pancreatitis occurs in some 
patients, this is not a usual cause of death. On the other 
hand, hypercholesterolemia is not so frequent, and when 
present, it is mild. Less than one-fourth of patients (10 
of 44, 22.7 %) had total cholesterol greater than 200 mg/
dl. But we know that patients with hypertriglyceridemia 
have a higher concentration of small and dense LDL [28] 
and, consequently, a higher cardiovascular risk. This 
can be confirmed in our patients who had a myocar-
dial infarction and atherosclerotic leg ulcers at an early 
age. HDL cholesterol is always very low, as expected in 
patients with hypertriglyceridemia, and no patient had 
HDL higher than 45  mg/dl. Hypertriglyceridemia, low 
HDL, and small and dense LDL are essential parts of the 
atherogenic triad seen in metabolic syndrome and also 
in our patients [28, 29]. Improvements in the lipid profile 
seen in patients using metreleptin (an analog of human 
leptin) confirm the important role of leptin in the treat-
ment of dyslipidemia [30]. The mechanisms by which 
leptin improves insulin resistance are not yet known 
[22]. It seems that there is a reduction in fat deposition 
in the liver and muscles [31]. None of our patients was 
on metreleptin. Despite its approval for BSCL in other 
countries, metreleptin is not yet available in Brazil.
Hepatic steatosis is part of the syndrome, but liver 
enzyme elevation was not frequent in our series. Two-
thirds of the patients had liver enzymes within the 
normal range. We must remember that the aminotrans-
ferases are not reliable predictors of steatohepatitis and 
several patients with normal aminotransferases may have 
steatohepatitis when undergoing liver biopsy [32].
Conclusions
We report one of the largest series of patients with 
BSCL treated at a single medical center. The lack of 
genetic analysis in one-third of the patients is a limita-
tion to the best clinical characterization of the group. We 
believe that since the majority of patients were from the 
same region, two-thirds of the patients who already had 
genetic diagnosis must represent the proportion of the 
types of BSCL in this population. We hope that earlier 
clinical/genetic diagnosis and more efficient treatment 
options can reduce complications, prevent early deaths, 
and thus increase the expectation and quality of life of 
these patients.
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